ASX 200 healthcare stock Sonic Healthcare Ltd (ASX: SHL) is enjoying a strong session, with shares currently 4% higher at $27.30 apiece.
The moves follow updates from the healthcare giant's Annual General Meeting (AGM), with plenty of comments made by the company's chairman.
Zooming out, the stock is down 16% this year to date, trailing the broader indexes. Let's take a closer look.
ASX 200 healthcare stock's AGM takeouts
During its AGM, the ASX 200 healthcare stock provided a comprehensive update on its financial health and strategic outlook.
Chairman Mark Compton emphasised the company's financials, citing growth in its base business and its expanding global footprint across seven countries.
The company reported $9 billion in revenue for FY24, though net profit fell to $511 million due to an expected drop in COVID-19 testing revenues.
Whilst this may seem concerning at face value, management fully anticipated this. There's no longer a pandemic, and vaccination rates are high.
As such, sales excluding COVID-related revenue were up 16% year over year, including 600 basis point growth in its "base business".
Compton also noted that Sonic Healthcare's dividend increased by 2% to $1.06 per share, which is a nice reward for shareholders.
He also highlighted that its balance sheet remains strong, with gearing below pre-pandemic levels.
The Company's balance sheet remains in a very strong position, with gearing still below pre-pandemic averages, despite the significant investments made during the 2024 year. This strength will enable the Company to take advantage of additional sensible growth opportunities as they arise.
To ensure that the strong governance required to oversee the Company's growth is in place and effective, we continue to focus on the development, renewal and diversity of the membership of
Sonic's Board of Directors and Board Committees.
Sonic also announced some board changes this week. Nicola Wakefield Evans will join the ASX 200 healthcare stock board in 2025. The board now includes seven independent and non-executive directors and two executive directors. These directors range from medical professionals to the CEO and CFO, respectively.
Why are investors so optimistic?
The optimism around Sonic appears to stem from both its financial footing and growth strategy.
Management is focused on earnings growth into the future and says there are plenty of drivers to see higher profits in coming years. According to the chairman:
The outlook is for earnings growth in future periods, driven by:
– ongoing strong organic revenue growth with consequent operating leverage;
– cost reduction programs and other earnings initiatives implemented during the 2024 and
current year; and
– the realisation of synergies and enhanced earnings from completed acquisitions and technology
investments.The confidence we have in our earnings outlook, together with our strong balance sheet, allowed us
to continue our progressive dividend policy, rewarding shareholders with a 2% increase in dividends
over the previous year, to $1.06 per share.
Changes in stock prices are, in part, set by changes in expectations. That is, expectations of growth, earnings, and the broader economy.
Providing colour on the growth drivers could inflect positively on an ASX 200 healthcare stock like Sonic, in my view.
Sustainability also featured prominently at the AGM, with Sonic's 2024 Sustainability Report outlining achievements in environmental and social governance (ESG).
ASX 200 healthcare stock takeaway
Sonic Healthcare is a $13 billion ASX 200 healthcare stock that's been beaten down in 2024.
If today's price action is any indication, things might be starting to look up for the share. Investors are reacting positively to takeouts from the company's AGM.
Zooming out, the ASX healthcare stock is down nearly 8% in the past year.
